Inactive Instrument

Other languages Can Fite Biopharma Ltd TEL AVIV STOCK EXCHANGE

Equities

IL0010944739

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study	Apr. 03
Can-Fite Biopharma Ltd. Announces Clinical Update	Mar. 28
Can-Fite BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Can-Fite Biopharma Ltd. to Present Data from the Pancreatic and Liver Cancer Programs	Mar. 11
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the Canadian Intellectual Property Office	Feb. 28
Can-Fite BioPharma Ltd. Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication	Jan. 30
Can-Fite Biopharma Ltd. Announces Results from Randomized Phase 3 Clinical Trial	Jan. 29
Can-Fite BioPharma Ltd. Reports New Data on Namodenoson?s Anti-Obesity Mechanism of Action	Dec. 20
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan	Dec. 18
Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson	Dec. 18
Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients	Dec. 04
Can-Fite BioPharma Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 30
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon	Nov. 21
Top Midday Gainers	Nov. 21
Can-Fite Biopharma Reports 'Complete Response' in Liver Cancer Patient Treated With Namodenoson	Nov. 21
Top Premarket Gainers	Nov. 21
Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson	Nov. 21
Can-Fite Biopharma Ltd. Provides Business Update	Nov. 01
Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal	23-10-30
Can-Fite Biopharma Ltd. Enters into an Agreement with Collaborations Pharmaceuticals Inc to Develop Anti-Cancer Drugs Utilizing Artificial Intelligence	23-10-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Can Fite Biopharma Ltd TEL AVIV STOCK EXCHANGE

Equities

IL0010944739

Other languages

Filters